Sussel Vega Pupo
Family · Coral Springs, FLNPI 1376137166
Payments from drug & device makers
Across 50 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$361
- Tanabe Pharma America, Inc.$128
- Stryker$72
- Aprecia Pharmaceuticals, LLC$66
- Lundbeck LLC$57
- Sanofi$47
- plus $336 from 13 others
What the payments were for
- Food & beverage$1,066100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $361 |
| Tanabe Pharma America, Inc. | 4 | $128 |
| Stryker | 1 | $72 |
| Aprecia Pharmaceuticals, LLC | 3 | $66 |
| Lundbeck LLC | 3 | $57 |
| Sanofi | 2 | $47 |
| Argenx US, Inc. | 2 | $46 |
| Acadia Pharmaceuticals Inc | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Eisai Inc. | 2 | $37 |
| CSL Behring | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 2 | $25 |
| Amgen | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$1,066 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 109 | $1,950 |
| Gabapentin | 80 | $1,318 |
| Memantine Hcl ErMemantine Hcl | 12 | $1,157 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 38 | $1,095 |
| Levetiracetam | 28 | $1,058 |
| Donepezil Hcl | 95 | $899 |
| Duloxetine Hcl | 28 | $739 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 16 | $703 |
| Quetiapine Fumarate | 21 | $419 |
| Topiramate | 25 | $393 |
| Pregabalin | 11 | $293 |
| Primidone | 17 | $278 |
| Lamotrigine | 15 | $261 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 21 | $190 |
| ClopidogrelClopidogrel Bisulfate | 12 | $160 |
Paid to pharmacies, not to this prescriber.
Other family in Coral Springs
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.